Amneal receives approval for difluprednate ophthalmic emulsion

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced that it has received abbreviated new drug application (anda) approval from the u.s. food and drug administration (fda) for difluprednate ophthalmic emulsion 0.05%, which is the generic version of durezol® and is used in the treatment of inflammation and pain associated with ocular surgery. “with the approval of difluprednate, a complex ophthalmic suspension product, we conti
AMRX Ratings Summary
AMRX Quant Ranking